141 related articles for article (PubMed ID: 34425200)
1. Installation of high-affinity Siglec-1 ligand on tumor surface for macrophage-engaged tumor suppression.
Zhang E; Wen S; Quan J; Han J; Cao H; Han S
Bioorg Med Chem Lett; 2021 Oct; 50():128328. PubMed ID: 34425200
[TBL] [Abstract][Full Text] [Related]
2. Metabolic installation of macrophage-recruiting glycan ligand on tumor cell surface for in vivo tumor suppression.
Xie Y; Li Y; Han S
Bioorg Med Chem Lett; 2022 Feb; 57():128500. PubMed ID: 34906672
[TBL] [Abstract][Full Text] [Related]
3. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
4. Viewing Siglecs through the lens of tumor immunology.
Fraschilla I; Pillai S
Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
[TBL] [Abstract][Full Text] [Related]
5. Mouse Siglec-1 Mediates trans-Infection of Surface-bound Murine Leukemia Virus in a Sialic Acid N-Acyl Side Chain-dependent Manner.
Erikson E; Wratil PR; Frank M; Ambiel I; Pahnke K; Pino M; Azadi P; Izquierdo-Useros N; Martinez-Picado J; Meier C; Schnaar RL; Crocker PR; Reutter W; Keppler OT
J Biol Chem; 2015 Nov; 290(45):27345-27359. PubMed ID: 26370074
[TBL] [Abstract][Full Text] [Related]
6. Sialoside analogue arrays for rapid identification of high affinity siglec ligands.
Blixt O; Han S; Liao L; Zeng Y; Hoffmann J; Futakawa S; Paulson JC
J Am Chem Soc; 2008 May; 130(21):6680-1. PubMed ID: 18452295
[TBL] [Abstract][Full Text] [Related]
7. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
8. Identification and functional characterization of a Siglec-7 counter-receptor on K562 cells.
Yoshimura A; Asahina Y; Chang LY; Angata T; Tanaka H; Kitajima K; Sato C
J Biol Chem; 2021; 296():100477. PubMed ID: 33640457
[TBL] [Abstract][Full Text] [Related]
9. Sialoglycans on lymphatic endothelial cells augment interactions with Siglec-1 (CD169) of lymph node macrophages.
D'Addio M; Frey J; Tacconi C; Commerford CD; Halin C; Detmar M; Cummings RD; Otto VI
FASEB J; 2021 Nov; 35(11):e22017. PubMed ID: 34699642
[TBL] [Abstract][Full Text] [Related]
10. High-affinity ligands of Siglec receptors and their therapeutic potentials.
Magesh S; Ando H; Tsubata T; Ishida H; Kiso M
Curr Med Chem; 2011; 18(23):3537-50. PubMed ID: 21756229
[TBL] [Abstract][Full Text] [Related]
11. Probing sialic acid binding Ig-like lectins (siglecs) with sulfated oligosaccharides.
Rapoport EM; Pazynina GV; Sablina MA; Crocker PR; Bovin NV
Biochemistry (Mosc); 2006 May; 71(5):496-504. PubMed ID: 16732727
[TBL] [Abstract][Full Text] [Related]
12. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand.
Tateno H; Crocker PR; Paulson JC
Glycobiology; 2005 Nov; 15(11):1125-35. PubMed ID: 15972893
[TBL] [Abstract][Full Text] [Related]
13. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
14. The role of sialic acid-binding immunoglobulin-like-lectin-1 (siglec-1) in immunology and infectious disease.
Prenzler S; Rudrawar S; Waespy M; Kelm S; Anoopkumar-Dukie S; Haselhorst T
Int Rev Immunol; 2023; 42(2):113-138. PubMed ID: 34494938
[TBL] [Abstract][Full Text] [Related]
15. Effect of cytokines on Siglec-1 and HIV-1 entry in monocyte-derived macrophages: the importance of HIV-1 envelope V1V2 region.
Jobe O; Trinh HV; Kim J; Alsalmi W; Tovanabutra S; Ehrenberg PK; Peachman KK; Gao G; Thomas R; Kim JH; Michael NL; Alving CR; Rao VB; Rao M
J Leukoc Biol; 2016 Jun; 99(6):1089-106. PubMed ID: 26667473
[TBL] [Abstract][Full Text] [Related]
16. Gangliosides as Siglec ligands.
Schnaar RL
Glycoconj J; 2023 Apr; 40(2):159-167. PubMed ID: 36701102
[TBL] [Abstract][Full Text] [Related]
17. Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens.
Spiller F; Nycholat CM; Kikuchi C; Paulson JC; Macauley MS
J Immunol; 2018 Feb; 200(3):949-956. PubMed ID: 29288201
[TBL] [Abstract][Full Text] [Related]
18. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.
Läubli H; Alisson-Silva F; Stanczak MA; Siddiqui SS; Deng L; Verhagen A; Varki N; Varki A
J Biol Chem; 2014 Nov; 289(48):33481-91. PubMed ID: 25320078
[TBL] [Abstract][Full Text] [Related]
19. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
[TBL] [Abstract][Full Text] [Related]
20. Sialic Acid-Siglec-E Interactions During
Mukherjee K; Khatua B; Mandal C
Front Immunol; 2020; 11():332. PubMed ID: 32184783
[No Abstract] [Full Text] [Related]
[Next] [New Search]
